FDA Determines Regulatory Review Period for Livostin Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Livostin, a human drug product, as required by law, following a patent extension application submitted to the Commissioner of Patents and Trademarks, Department of Commerce.